T cell Targeting for Cancers and Autoimmune Diseases

Reference Sustained Effect Theory

Angimmune LLC is the developer of a high potency fusion protein anticancer immunotoxin, A-dmDT390-bisFv(UCHT1) (Resimmune®). Resimmune® has been granted Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Licensing & Collaboration

Angimmune welcomes inquiries regarding licensing of its technologies.